Type 2 diabetes: Complications and comorbidities

The results of the DECLARE-TIMI 58 trial show a broadly positive effect of dapagliflozin on cardiovascular outcomes, especially heart failure, in patients with type 2 diabetes.

The final version of the 2018 update to the consensus guidelines on managing hyperglycemia in people with type 2 diabetes is now published.

Weekly application of an autologous immune cell, fibrin, and platelet patch significantly increases the rate of healing of hard-to-heal foot ulcers compared with standard care in people with diabetes, randomized trial data show.

Advisory Board member Theresa Smyth tackles an emergency case in a type 2 diabetes patient treated with empagliflozin. What went wrong and how should he be managed?

The weight-loss medication lorcaserin neither increases nor reduces cardiovascular risk, report the CAMELLIA–TIMI 61 investigators.

Researchers have found evidence to support an increased risk for amputation among patients with type 2 diabetes taking sodium-glucose cotransporter 2 inhibitors relative to some oral treatments.

Uazman Alam and colleagues interrogate current evidence and real-world clinical scenarios to address whether enough is being done with the tools available to screen and diagnose diabetic neuropathy.

Obese patients with type 2 diabetes who undergo bariatric surgery achieve large reductions in their risk for microvascular complications, shows a real-world study.

Research shows that starting second-line sulfonylurea treatment is associated with an increased risk for cardiovascular and hypoglycemic events among patients with type 2 diabetes in clinical practice, although the risk is less if they continue using metformin rather than switching completely.

A study of patients from US administrative claims databases finds no evidence that use of canagliflozin increases the risk for below the knee amputation when compared with other sodium-glucose cotransporter 2 inhibitors or with other antidiabetic medications.

Papadopoulou E et al. J Hum Hypertens 2018. doi: 10.1038/s41371-018-0079-5

Zhu B et al. Acta Diabetol 2018. doi: 10.1007/s00592-018-1181-4

Nishimura A et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0457-6

Dave N, Wu J, Thomas S. Curr Diab Rep 2018; 18: 44. doi: 10.1007/s11892-018-1010-8

Einarson TR et al. Cardiovasc Diabetol 2018; 17: 83. doi: 10.1186/s12933-018-0728-6

Editorial Board member Lori Berard talks through the stages and challenges associated with preparing type 2 diabetes patients for insulin therapy (9:00).

Sanjay Kalra and Silver Bahendeka, East Africa Diabetes Study Group Chair, provide an overview of the latest insulin guidance developed to aid management in a challenging region, facing familiar struggles.

Deng Z et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0448-7

Maskarinec G et al. Eur J Clin Nutr 2018. doi: 10.1038/s41430-018-0188-9

Nichol AD, Holle MJ, An R. Eur J Clin Nutr 2018. doi: 10.1038/s41430-018-0170-6